In mice, it was found that increased expression of tumor INHBA led to decreased PD-L1 expression and decreased efficacy of anti-PD-L1 therapy, atezolizumab, which is thought to work via decreased signaling through IFN-γ [175]. Here, CD274 is linked to neoplasm.